The imaging substudy is an afterthought in the protocol and the centrepiece of the debate

What the substudies found is not in serious dispute. In both programmes, the proportion of body mass that was fat fell and the proportion that was lean rose, which is the arithmetic signature of losing more fat than lean tissue. In both, the absolute quantity of lean mass also fell, because a person shedding a fifth of their body weight sheds some of everything. Whether that second fact matters is where the evidence stops and the interpretation starts, and the interpretation has been conducted at a volume wholly disproportionate to the underlying data.

What the semaglutide DXA substudy measured

In the STEP 1 trial of once-weekly semaglutide 2.4 mg in adults with overweight or obesity without diabetes, mean weight reduction at sixty-eight weeks was approximately 14.9 per cent against 2.4 per cent on placebo.¹ A body-composition substudy conducted at a subset of sites scanned approximately one hundred and forty participants by dual-energy X-ray absorptiometry at baseline and at week sixty-eight.

The substudy reported a reduction in total fat mass of roughly nineteen per cent in the semaglutide group, a smaller absolute reduction in lean body mass, and consequently an increase in the proportion of total body mass that was lean — from approximately fifty-seven per cent at baseline to approximately sixty-one per cent at week sixty-eight. Regional visceral fat mass fell proportionally more than total fat mass, which is the metabolically favourable direction.

Converted into the currency people argue in, roughly a third to two-fifths of the total mass lost in that substudy was lean tissue by the DXA definition. That is unremarkable against the dietary weight-loss literature. It is also a group mean from one hundred and forty people, reported at a single follow-up point, with no strength or function measurement alongside it.

The tirzepatide substudy, and the ratio it reported

SURMOUNT-1 randomised adults with obesity or overweight without diabetes to tirzepatide at 5, 10 or 15 mg weekly or placebo for seventy-two weeks, with mean weight reduction of approximately 20.9 per cent at the highest dose against 3.1 per cent on placebo.² A DXA substudy of approximately one hundred and sixty participants measured composition at baseline and at week seventy-two.

The reported result is usually summarised as a three-to-one ratio: total fat mass fell by roughly a third while lean mass fell by roughly a tenth, so approximately three-quarters of the mass lost was fat. The substudy also reported that the ratio of fat mass to lean mass change was more favourable on tirzepatide than on placebo, which is the comparison that matters and the one most often omitted, because placebo participants who lost a small amount of weight lost a proportionally larger share of it as lean tissue.

The Journal notes two limits on this figure. It is a mean across three dose arms pooled in some analyses and reported separately in others, and secondary coverage rarely says which. And a favourable ratio applied to a very large total loss still yields a substantial absolute lean-mass reduction, which is the legitimate residue of the concern.

The magnetic-resonance substudy in the diabetes programme

The most methodologically interesting composition data in this class did not come from an obesity trial. A magnetic-resonance imaging substudy within SURPASS-3, comparing tirzepatide against insulin degludec in type 2 diabetes, measured liver fat content and abdominal adipose tissue volumes rather than whole-body compartments.³ Approximately three hundred participants were imaged, which makes it the largest imaging substudy in the programme.

Liver fat content fell substantially more on tirzepatide than on insulin, as did visceral adipose tissue volume, and the separation between the arms was larger than the difference in total body weight would predict. That is the single most useful composition finding in the class, because it shows the two interventions redistributing tissue differently rather than merely producing different amounts of weight change.

Magnetic resonance is the better instrument for this question by some distance: it measures adipose tissue volumes directly and separates visceral from subcutaneous depots, neither of which DXA does well. It is also expensive, slow and unavailable at most trial sites, which is why the whole-body composition argument is still being conducted on DXA data from a few hundred people.

What the substudies were never powered to detect

An imaging substudy inside a large trial is sized to describe rather than to test. The enrolment is set by how many participating sites have a scanner and by what the sponsor budgeted, not by a power calculation against a composition hypothesis, and the analysis is generally pre-specified as exploratory or descriptive. The consequence is that these substudies can report a mean change with a usable confidence interval and cannot support most of the questions asked of them.

They cannot, for instance, establish whether lean-mass change differs between dose arms, because the per-arm enrolment after splitting is in the low tens. They cannot establish whether it differs by age, sex, baseline adiposity or diabetes status, because those subgroups were not enrolled to be comparable. They cannot describe the distribution of individual responses, because the per-participant least significant change is a substantial fraction of the observed mean effect. And they cannot address function at all, because nobody measured it.

Nor was the imaging repeated when the programmes were extended. The two-year semaglutide extension reported weight, waist circumference and cardiometabolic parameters at week 104 and did not repeat the composition substudy, so there is no imaging at all beyond seventy-two weeks in this class.⁴ Whatever the trajectory of lean mass is in year two of treatment, nobody has measured it.

None of this is a scandal; it is the ordinary economics of trial substudies. It becomes a problem only when a descriptive group mean is quoted as though it characterised what will happen to an individual, which is now the normal register of coverage on this subject.

The endpoint nobody measured

The clinical question is not how many kilograms of lean tissue a person has. It is whether they can climb stairs, rise from a chair without using their arms, carry shopping, and recover from an illness that keeps them in bed for a week. Those are measurable — grip strength, gait speed, chair-stand time, stair-climb power, the short physical performance battery — and they are measured routinely in geriatrics and sports science. Not one phase 3 trial in this drug class has reported them as a pre-specified endpoint.

That absence is the strongest available criticism of the programmes, and it has been made in the general medical literature by authors who are otherwise unsympathetic to muscle-loss alarmism.⁵ Their argument is worth stating precisely: the concern about lean-mass loss is plausible but unquantified, the instrument used to assess it is a poor proxy for the tissue of interest, and the endpoints that would settle whether it matters are cheap, validated and were simply not collected.

Where function has been measured during substantial weight loss by other routes, the results are mostly reassuring: physical performance usually improves, because carrying less mass is itself a functional benefit. That is a reasonable prior and it is not a substitute for the measurement.

The Journal position on body composition is narrower than either camp would like. The drugs produce weight loss whose composition is, on the available imaging, at least as favourable as dietary weight loss and probably slightly better. The absolute lean-mass reduction accompanying a twenty per cent weight loss is nevertheless substantial, is unmeasured in functional terms, and is a reasonable thing for an older or already frail person to want managed. Both of those sentences are true and the argument has largely consisted of people insisting on one of them.